19 terminated, 7 completed, 6 withdrawn, 2 active not recruiting. 20 Phase 1, 17 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 7, Terminated 7, Withdrawn 4, Active not recruiting 2 |
| Phase 2 | 17 | Terminated 13, Withdrawn 3, Completed 1 |
| Phase 3 | 3 | Terminated 3 |
Follow magrolimab: new trials by email Literature Review of magrolimab trials Research Report on magrolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants Sabatolimab, Magrolimab, Azacitidine - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2024-12-20 | 2024-04-11 | |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-10-09 | 2024-09-19 | |
| Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS Magrolimab, 7+3, CPX-351 - Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Withdrawn | Uwe Platzbecker | 2024-03-31 | 2024-02-12 | |
| Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2024-03-05 | 2024-05-02 | |
| Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma Pembrolizumab, Magrolimab, cetuximab - Head Neck, Squamous Cell Carcinoma of Head and Neck | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2023-11-28 | 2025-10-22 |
| An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Magrolimab, Rituximab, CAR T leukapheresis - Large B-cell Lymphoma, B-cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-09-30 | 2023-11-13 | |
| A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) Decitabine/Cedazuridine, Magrolimab - Myelodysplastic Syndromes | Phase 2 | Terminated | Astex Pharmaceuticals, Inc. | 2 | 2023-06-27 | 2024-10-02 |
| Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma Magrolimab, Cisplatin, Gemcitabine - Advanced Urothelial Carcinoma | Phase 1 | Withdrawn | Insel Gruppe AG, University Hospital Bern | 2023-06-21 | 2024-07-05 | |
| Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) Magrolimab, Bevacizumab, Irinotecan - Metastatic Colorectal Cancer | Phase 2 | Terminated | Gilead Sciences | 77 | 2022-07-08 | 2025-07-01 |
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia Magrolimab, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 3 | Terminated | Gilead Sciences | 378 | 2022-07-07 | 2025-04-04 |
| Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma Magrolimab, Pembrolizumab, PET/CT - Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Terminated | Ranjana Advani | 8 | 2022-06-21 | 2026-06-30 |
| Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Magrolimab - Brain Cancer, Malignant Brain Tumor | Phase 1 | Completed | University of California, San Francisco | 13 | 2022-04-22 | 2025-07-09 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Obinutuzumab, Venetoclax, Magrolimab - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2021-12-16 | 2025-02-04 |
| Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer Magrolimab, Nab-Paclitaxel, Paclitaxel - Triple-Negative Breast Cancer | Phase 2 | Terminated | Gilead Sciences | 92 | 2021-12-14 | 2025-11-04 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma Magrolimab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 2 | Terminated | Gilead Sciences | 36 | 2021-11-09 | 2025-05-02 |
| Study of Magrolimab in Patients With Solid Tumors Magrolimab, Docetaxel - Solid Tumor | Phase 2 | Terminated | Gilead Sciences | 106 | 2021-10-01 | 2025-05-08 |
| The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer ONO-7913, ONO-4538, Fluorouracil - Unresectable Colorectal Cancer | Phase 1 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 65 | 2021-09-23 | 2026-10-07 |
| Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma Magrolimab, Pembrolizumab, Docetaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Gilead Sciences | 193 | 2021-09-07 | 2025-11-19 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2021-08-31 | 2026-06-30 |
| An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer ONO-7913, ONO-4538, Oxaliplatin - Metastatic Pancreatic Cancer | Phase 1 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 32 | 2021-07-30 | 2026-10-07 |
Showing 20 of 35. Sign in to see all of them.
Leukemia, Myeloid, Acute (9) · Myelodysplastic Syndromes (5) · Colorectal Neoplasms (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Squamous Cell Carcinoma of Head and Neck (2) · Anemia, Refractory, with Excess of Blasts (1) · Brain Neoplasms (1) · Carcinoma, Transitional Cell (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Gilead Sciences (16) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Hoffmann-La Roche (2) · Ono Pharmaceutical Co., Ltd. (2) · Acerta Pharma BV (1) · Astex Pharmaceuticals, Inc. (1) · City of Hope Medical Center (1) · Insel Gruppe AG, University Hospital Bern (1) · Novartis Pharmaceuticals (1) · Ranjana Advani (1) · University of California, San Francisco (1) · Uwe Platzbecker (1)
United States (26) · United Kingdom (12) · Australia (8) · France (7) · Spain (7) · Canada (6) · Hong Kong (6) · Belgium (5) · Germany (5) · Italy (5) · Poland (4) · Austria (3) · Czechia (3) · Japan (3) · South Korea (3)
Project Leader (2) · Bernhard Kiss, Professor (1) · Chris Takimoto, MD (1) · Haider S Mahdi (1) · Howard Colman, MD PhD FAAN (1) · Ian Flinn, MD, PhD (1) · Mark Chao, MD PhD (1) · Mark J Roschewski, M.D. (1) · Michael S Khodadoust (1) · Monzr M Al Malki, MD (1) · Naval G Daver (1) · Nicholas Whipple, MD, MPH (1)
PMID 36888930, PMID 37703506, PMID 26390038, PMID 30811285, PMID 31183877, PMID 37651261, PMID 39213421, PMID 39293083, PMID 40009500, PMID 40233321, PMID 40318595, PMID 40364806, PMID 40485906, PMID 42441929
2017 (2), 2015 (1), 2016 (1), 2023 (1), P30CA015704 (1), P30CA033572 (1), U01CA154967 (1), UM1CA186690 (1), UM1CA186717 (1), UM1CA228823 (1)